The Australia CDMO market was valued at USD 2.03 Billion in 2025 and is expected to grow at a CAGR of 7.00%, reaching USD 3.99 Billion by 2035. The market growth is driven by its strong regulatory environment and advanced clinical trial infrastructure across the region. The growing demand for localized sterile injectables and biologics production further supports opportunities for domestic and international investment, driving sustained sector growth.
Base Year
Historical Period
Forecast Period
Vertical integration via BioCina-NovaCina collaboration provides Australia with robust end-to-end biologics CDMO capabilities.
Bridgewest’s acquisition and launch of NovaCina significantly expand Australia’s sterile injectable manufacturing scale under GMP.
Substantial investment in MRFF funding for clinical and manufacturing infrastructure enhances domestic CDMO offerings and global market alignment.
Compound Annual Growth Rate
7%
Value in USD Billion
2026-2035
*this image is indicative*
Australia’s CDMO market underpins national biopharma self-reliance by delivering advanced manufacturing, from injectables to mRNA and biologics. Combining government funding, strong regulatory oversight, and world-class infrastructure, it supports clinical and commercial production, boosts innovation, and attracts global partnerships, positioning Australia as a hub for high-quality contract manufacturing. Australia boasts world-class infrastructure that supports the entire lifecycle of drug development and manufacturing. The country has advanced facilities capable of handling a variety of manufacturing needs, including sterile injectables, biologics, and more recently, mRNA vaccines and therapies. This infrastructure is crucial in positioning Australia as a hub for high-quality contract manufacturing.
Thanks to rising healthcare needs and national biotech ambitions, public funding is backing CDMO expansion. For instance, in January 2025, the Medical Research Future Fund allocated AUD 35.7 million (USD 23.5 million) to enhance clinical trial and manufacturing infrastructure. This investment bolsters early-stage development capacity and draws global pharma interest, supporting growth in Australia’s CDMO capabilities and bolstering its reputation for quality manufacturing.
Major market trends include vertical integration of biologics services and expansion of sterile injectable manufacturing infrastructure.
Vertical Integration to Enable Comprehensive Biologic Services
With rising R&D investment and demand for pandemic-response capacity, Australia is building end-to-end biologics CDMO capabilities. For instance, in February 2024, BioCina and NovaCina partnered to link their Adelaide and Perth facilities, offering seamless drug-substance-to-product manufacturing for plasmid DNA, mRNA, and biologics. This integration enhances operational efficiency, supports domestic therapeutic pipelines, and raises Australia’s industry appeal for international biologics outsourcing.
Strategic Acquisitions to Meet Rising Australia CDMO Market Demand
Driven by need for local GMP facilities and diversification of therapeutic portfolios, acquisition-based growth is reshaping the CDMO market in Australia. For instance, in April 2023, Bridgewest Group acquired Pfizer's Perth sterile injectable plant and launched NovaCina, offering nine production lines, including oncology and high-potency injectables. This acquisition secures continuity for Pfizer products while boosting regional manufacturing scale and regulatory compliance, strengthening Australia’s role in global CDMO supply chains.
Pharmaceutical and Biopharmaceutical Companies to Lead the Market by End Users
The pharmaceutical and biopharmaceutical companies are expected to dominate the segmentation by end user. It is supported by a robust CAGR of 7.3% in the CMO segment and 6.2% in the CRO segment. This leadership is driven by increased public funding, advanced biologics infrastructure, and growing demand for localized production. Major developers are increasingly partnering with CDMOs such as BioCina and Catalent for GMP-compliant, end-to-end manufacturing services. As the pipeline for injectables, biologics, and mRNA therapies expands, this segment continues to be the primary engine of market growth.
The key features of the market report comprise grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Somerset, New Jersey, Catalent Inc. was established in 2007 and has significantly expanded its presence in Australia through specialized biologics and sterile manufacturing capabilities. The company operates a notable facility in Melbourne focused on early-phase development and clinical-scale biologics manufacturing. Catalent's Australian site supports regional pharmaceutical firms and global clients with GMP-certified capabilities. Its local operations are integrated into the company’s global network, enabling streamlined tech transfer and accelerated production timelines. Strategic investments in Australian biomanufacturing underline Catalent’s commitment to enhancing Asia-Pacific CDMO services.
Founded in 1995 and based in Stockholm, Sweden, Recipharm AB has strengthened its footprint in the Australian CDMO market through tailored services in drug substance and drug product manufacturing. Although it does not operate a direct facility in Australia, Recipharm engages through strategic collaborations with local firms for packaging, serialization, and clinical supply solutions. The company’s global compliance framework and flexible service model make it an attractive outsourcing partner for Australian biopharma clients aiming to export to Europe and North America under strict regulatory standards.
Boehringer Ingelheim, established in 1885 in Ingelheim, Germany, operates globally with a focus on biologics and advanced therapeutics. In Australia, the company contributes to the CDMO market by leveraging its global capabilities to support local partners through tech transfer, fill-finish operations, and regulatory consulting. While it doesn’t maintain standalone CDMO facilities in the country, its established R&D and commercial operations in Sydney and Melbourne serve as a platform for integrated services. The company also collaborates on early-phase clinical development, fostering innovation in the Australian pharmaceutical manufacturing sector.
Patheon, a division of Thermo Fisher Scientific based in Waltham, Massachusetts, has expanded into Australia through its acquisition-led strategy. Although Patheon does not own a direct manufacturing site in the country, it provides CDMO services via a global network that supports Australian biotech and pharma firms in biologics development, regulatory submissions, and clinical supply. The company’s services are often accessed through partnerships or Australian contract trials facilitated via Thermo Fisher’s CRO segment, contributing to capacity expansion and tech-driven drug development across the region.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Samsung Biologics Co., Ltd., Lonza Group, WuXi AppTec, Fareva SA, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share